



HAL
open science

Prevalence of mutations in the *Plasmodium falciparum* chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African *Plasmodium falciparum* isolates

Francis Tsombeng Foguim, Hervé Bogreau, Mathieu Gendrot, Joel Mosnier, Isabelle Fonta, Nicolas Benoit, Rémy Amalvict, Marylin Madamet, Sharon Wein, Bruno Pradines

► To cite this version:

Francis Tsombeng Foguim, Hervé Bogreau, Mathieu Gendrot, Joel Mosnier, Isabelle Fonta, et al.. Prevalence of mutations in the *Plasmodium falciparum* chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African *Plasmodium falciparum* isolates. *Malaria Journal*, 2020, 19 (1), 10.1186/s12936-020-03281-x . hal-02996272

HAL Id: hal-02996272

<https://hal.science/hal-02996272>

Submitted on 20 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH

Open Access



Prevalence of mutations in the *Plasmodium falciparum* chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African *Plasmodium falciparum* isolates

Francis Tsombeng Foguim^{1,2,3}, Hervé Bogreau^{1,2,3}, Mathieu Gendrot^{1,2,3}, Joel Mosnier^{1,2,3,4}, Isabelle Fonta^{1,2,3,4}, Nicolas Benoit^{1,2,3,4}, Rémy Amalvict^{1,2,3,4}, Marylin Madamet^{1,2,3,4}, Sharon Wein⁵, Bruno Pradines^{1,2,3,4*} and The French National Reference Centre for Imported Malaria Study Group

Abstract

Background: The *Plasmodium falciparum* chloroquine transporter gene (*pfcr*) is known to be involved in chloroquine and amodiaquine resistance, and more particularly the mutations on the loci 72 to 76 localized within the second exon. Additionally, new mutations (T93S, H97Y, C101F, F145I, M343L, C350R and G353V) were recently shown to be associated with in vitro reduced susceptibility to piperazine in Asian or South American *P. falciparum* strains. However, very few data are available on the prevalence of these mutations and their effect on parasite susceptibility to anti-malarial drugs, and more particularly piperazine in Africa.

Methods: A molecular investigation of these mutations was performed in 602 African *P. falciparum* parasites collected between 2017 and 2018 on malaria patients hospitalized in France after a travel in African countries. Associations between genotypes and in vitro susceptibilities to piperazine and standard antimalarial drugs were assessed.

Results: None of the mutations, previously described as associated with piperazine resistance, was found in the 602 *P. falciparum* African isolates. The K76T mutation is associated with resistance to chloroquine ($p < 0.0002$) and desethylamodiaquine ($p < 0.002$) in Africa. The K76T mutation is not associated with in vitro reduced susceptibility to piperazine. The mutation I356T, identified in 54.7% ($n = 326$) of the African isolates, was significantly associated with reduced susceptibility to quinine ($p < 0.02$) and increased susceptibility to mefloquine ($p < 0.04$). The K76T and I356T mutations were significantly associated in West African isolates ($p = 0.008$).

Conclusion: None of the mutations in *pfcr* found to be associated with piperazine reduced susceptibility in Asia or South America (T93S, H97Y, C101F, F145I, M343L, C350R and G353V) were found in the 602 African isolates including the three isolates with reduced susceptibility to piperazine. The K76T mutation, involved in resistance to chloroquine and amodiaquine, and the I356T mutation were not associated with in vitro reduced susceptibility to piperazine.

*Correspondence: bruno.pradines@gmail.com

¹ Unité Parasitologie et entomologie, Département Microbiologie et maladies infectieuses, Institut de Recherche Biomédicale des Armées, IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005 Marseille, France

Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Differences in mefloquine susceptibility between I356 and 356T isolates were, while statistically different, minimal. Further analyses are needed with a more important sample size from the same geographic area to confirm the role of the I356T mutation on quinine susceptibility.

Keywords: Malaria, *Plasmodium falciparum*, Antimalarial drug, Resistance, In vitro, Molecular marker, *pfcr*, I356T, Africa

Background

The *Plasmodium falciparum* chloroquine transporter gene (*pfcr*) has been under different drugs pressure during parasites evolution for decades. As a result, acquisition of mutations for adaptation has emerged. These mutations induce an alteration of membrane protein physicochemical properties modifying vacuolar traffic of these drugs in resistant parasites [1]. Quinoline-based compounds like chloroquine, amodiaquine, mefloquine, primaquine, and piperazine share a similar structure [2]. The common and widely spread mutations on *pfcr* gene associated with resistance are localized within its second exon. Precisely, chloroquine resistance was associated with mutations on the loci 72–76 [1, 3]. The K76T mutation was associated with chloroquine resistance and used as molecular marker to survey chloroquine resistance in epidemiological studies [3]. But mutations on other loci were also found to be involved either as amplifying the resistance or as compensatory mutations for the fitness cost [4].

Since 2005, the World Health Organization (WHO) has recommended artemisinin-based combination therapy (ACT) as the first-line treatment against malaria. However, *P. falciparum* parasites resistant to artemisinin derivatives rapidly emerged in Southeast Asia, and more particularly in western Cambodia, Myanmar, Thailand and Laos [5, 6]. More recently, the emergence of *P. falciparum* resistance to dihydroartemisinin-piperazine was observed in Cambodia, where recrudescence infections had rapidly increased [7–9], and then in Vietnam [10, 11]. Duplication of the *P. falciparum* *Plasmepsin 2* gene (*pfpm2*), encoding a protease involved in haemoglobin degradation, has been found to be associated with reduced in vitro susceptibility to piperazine in Cambodian *P. falciparum* parasites and with dihydroartemisinin-piperazine failures in Cambodia [12, 13]. However, the involvement of *pfpm2* in piperazine resistance seems controversial in Africa [14]. Parasites from patients successfully treated with dihydroartemisinin-piperazine could carry with two copies of *pfpm2* while only a single copy of *pfpm2* was detected in isolates collected in imported malaria cases after dihydroartemisinin-piperazine failures or in *P. falciparum* isolates with in vitro reduced susceptibility to piperazine [15–20]. All these data suggest that *pfpm2* would not be the only gene that

explains the resistance to piperazine in Africa. Mutations in *pfcr* could be involved in piperazine resistance. The K76T mutation seems to be not associated with in vitro reduced susceptibility to piperazine [21]. However, several new mutations in *pfcr* were found to be associated with piperazine reduced susceptibility. Piperazine resistance, selected by in vitro continuous piperazine pressure on *P. falciparum* Dd2, was associated with the C101F mutation in *pfcr* on the same exon where the loci 72–76 are located [22, 23]. In 2012 in French Guiana, dihydroartemisinin-piperazine has not been yet officially recommended as first-line treatment against malaria but was used as self-medication by illegal gold miners in rainforest. Many years after the withdrawal of chloroquine as *P. falciparum* treatment, but still used for the treatment of *P. vivax* malaria, the prevalence of the mutant haplotype SVMNT (residues 72–76 in PfCRT) remained high (97.5%). In this context, the mutation C350R on *pfcr* emerged in 2002 to reach a prevalence of 58% in 2012. This mutation was involved in the decrease of in vitro susceptibility to piperazine with a restoration of chloroquine susceptibility [23]. In Cambodia, Agrawal and colleagues identified the substitution of phenylalanine by isoleucine on the locus 145 (F145I) associated with a decrease in piperazine susceptibility [25]. In a context of dihydroartemisinin-piperazine resistance in Cambodia and high prevalence of K13 C580Y mutation associated with artemisinin resistance, new *pfcr* mutations (H97Y, M343L, and G353V) were revealed to induce in vitro piperazine resistance [26, 27]. Treatment failures with dihydroartemisinin-piperazine were associated with T93S, H97Y, F145I and I218F mutations in PfCRT and with plasmepsin 2/3 amplification in Cambodia, Thailand and Vietnam [28, 29]. Many other mutations were found in *pfcr* but few were investigated for their association with anti-malarial drug resistance. The mutation I356T/L for instance is often found both on Asian or South-American parasites [30, 31].

These data suggest that parasite susceptibility to piperazine is affected by some of these mutations in Southeast Asia and South America. However, very few data are available on the prevalence of these mutations and their effect on parasites susceptibility to piperazine in Africa. It would, therefore, be essential to study these loci to provide more information on African parasites genotypes

and piperazine susceptibility. To this end, a molecular epidemiologic study of *pfprt* genotypes was conducted on 602 African *P. falciparum* parasites collected from different countries. The association between these mutations and ex vivo susceptibility to piperazine (PPQ) was assessed. Association with resistance to other common antimalarial drugs, such as chloroquine (CQ), quinine (QN), dihydroartemisinin (DHA), artesunate (AS) monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF) and pyronaridine (PND) was also evaluated.

Methods

Sample collection

A retrospective analysis was performed on 602 African *P. falciparum* samples collected between January 2017 and October 2018 on malaria patients hospitalized in France after a travel in sub-Saharan African countries (Table 1). The samples were sent from different civilian or military hospitals of the French National Reference Centre for Imported Malaria network (Aix en Provence, Bordeaux, Lyon, Marseille, Montpellier, Nice, Toulon and Toulouse) to the French National Reference

Table 1 Number of I256T and K76T mutations per regions and countries

Regions/countries	Allele I356 or 356T (number of samples)				Allele K76 or 76T (number of samples)			
	I356	Mixed	356T	Total	K76	Mixed	76T	Total
West Africa	145	17	139	301	197	13	68	278
Benin	6	1	6	13	2	1	6	9
Burkina Faso	9	1	10	20	16	1	2	19
Gambia	1	0	0	1	0	0	1	1
Ghana	2	0	4	6	6	0	0	6
Guinea	24	5	19	48	17	5	27	49
Ivory Coast	70	6	65	141	115	3	13	131
Mali	4	0	4	8	3	1	3	7
Niger	5	0	6	11	8	0	0	8
Nigeria	6	2	8	16	6	0	7	13
Senegal	7	2	4	13	6	2	5	13
Sierra Leone	1	0	3	4	3	0	3	6
Togo	9	0	10	19	15	0	1	16
Cape Verde	1	0	0	1				
Central Africa	101	12	116	229	179	10	40	229
Angola	0	0	2	2	2	0	0	2
Cameroon	54	4	65	123	106	4	15	125
Central African Republic	14	0	20	34	32	0	0	32
Chad	5	0	11	16	10	2	2	14
Congo	11	4	8	23	8	2	13	23
Gabon	17	4	10	31	21	2	10	33
East Africa	7	0	3	10	9	0	2	11
Burundi	1	0	1	2	1	0	1	2
Djibouti	1	0	1	2	1	0	1	2
Ethiopia	1	0	0	1	1	0	0	1
Mozambique	1	0	1	2	3	0	0	3
Sudan	1	0	0	1	1	0	0	1
Tanzania	2	0	0	2	2	0	0	2
Indian Ocean	12	0	23	35	31	1	1	33
Comoros	9	0	20	29	26	0	1	27
Madagascar	3	0	3	6	5	1	0	6
Maghreb	1	1	0	2	1	0	0	1
Morocco	1	1	0	2	1	0	0	1
Unknown origin	10	2	13	25	16	2	8	26
Total	276	32	294	602	433	26	119	578

Centre for Malaria (IRBA, IHU Méditerranée Infection, Marseille, France).

Nucleic acid extraction

DNA extraction for each sample was performed and purified using the QIAamp[®] DNA Mini kit according to the manufacturer's recommendations (Qiagen, Hilden, Germany).

pfcr genotyping

Two fragments of the *pfcr* gene (PF3D7_0709000) were amplified. The first fragment of 840 nucleotides including the exons 2, 3 and part of exon 4 and covering the positions 72–76, 93, 97, 101, 145, 146, 158 and 159 was amplified by PCR using the primers pairs: 5'-GAT-GGC-TCA-CGT-TTA-GGT-GGA-3' and 5'-TGT-TAC-AAC-AAT-AAT-AAC-TGC-TCC-G-3'. The second fragment of 339 nucleotides including the exon 10 and covering the positions 343, 350, 353 and 356 was amplified using the primer pairs: 5'-CCA-TAT-AAT-TTT-TCA-TTT-TC-3' and 5'-GTT-CTC-TTA-CAA-CAT-CAC-3'. The reaction mixture for PCR contained 200 ng of genomic DNA, 0.32 μ M of each primer, 1X final of reaction buffer (750 mM Tris-HCl, 200 mM (NH₄)₂SO₄, 0.1% (v/v) Tween 20 and stabilizer, pH 8.8), 2.5 mM MgCl₂, 200 μ M of dNTP mixture (Euromedex, Souffelweyersheim, France) and 0.2 U of Hot Diamond Taq[®] polymerase (Eurogentec, Liège, Belgium) in a final volume of 25 μ L. For the first fragment, the thermal cycler (Life Eco V 2.04; Bioer, China) was programmed as follows: 95 °C for 5 min, 40 cycles of 95 °C for 30 s, 65 °C of hybridization temperature for 1 min, elongation at 65 °C for 1 min 30 s, and a final 10-min extension step at 65 °C. The amplification programme for the second fragment was 95 °C for 5 min, 40 cycles of 95 °C for 30 s, hybridization temperature 46 °C for 45 s, elongation at 68 °C for 1 min, and a final 10 min extension step at 68 °C. To cover the mutations T93S, H97Y and C101E, the purified amplicons were sequenced by the amplification forward primer of the first fragment and the mutations F145I, I146L, F158L and V159S were sequenced using the primer 5'-TTA-GGA-ACG-ACA-CCG-AAG-C-3'. To cover the mutations M343L, C350R and I356T, the amplified second fragment was purified and sequenced using the forward primer. Sequencing was performed on ABI Prism 3100 analyser (Applied Biosystems, Villebon sur Yvette, France) according to the manufacturers' instructions. Base calling was implemented on Vector NTI 10.3.0 software (Invitrogen, Cergy Pontoise, France). Poor-quality sequences were either re-sequenced or discarded and repeat polymorphisms were retained for analysis if clean individual peaks were observed in the electropherogram.

Drugs and ex vivo assay

The drug susceptibility assays were performed using the HRP2 ELISA-based assay Malaria Ag Celisa kit (ref KM2159, Cellabs PTY LDT, Brookvale, Australia) as previously described [32].

Each batch of plates was validated using the CQ-resistant W2 strain (isolated from Indochina; MRA-157 obtained from MR4, VA, USA) in four independent experiments. The mean 50% inhibitory concentration (IC₅₀) values for all the batches used over 2 years were 495 \pm 45 nM for CQ, 401 \pm 36 nM for QN, 93 \pm 17 nM for DQ, 23.9 \pm 3.4 nM for MQ, 57.1 \pm 5.6 nM for PPQ, 18.6 \pm 3.1 nM for PND, 2.4 \pm 0.4 nM for DHA and 1.6 \pm 0.4 nM for AS. A comparison of the W2 anti-malarial susceptibility data between the different batches of plates indicated that there was no significant difference in the responses to anti-malarial drugs over the 2 years (0.625 < p < 0.990).

The polymorphic genetic markers *msp1* and *msp2* and microsatellite markers specific to *P. falciparum* W2 were genotyped at least once a month to verify W2 clonality as previously described [33–35].

Data management and statistical analysis

IC₅₀ values were calculated with the inhibitory sigmoid E_{max} model, with estimation of the IC₅₀ through non-linear regression using a standard function of the R software ICEstimator version 1.2 (<http://www.antimalarial-icestimator.net/>). IC₅₀s estimates values and sequences analysis were collected and analyzed on excel sheets and GraphPad Prism (V7.0a). Samples were grouped by regions for analysis to reflect parasites population structure sharing the same genetic background. The median of the IC₅₀ values was calculated for parasites with identical genotypes. Comparison between groups was implemented with Mann-Whitney test. Proportions were compared by Chi square test or Fisher exact test depending on sample size at significance level of 0.05.

Results

pfcr mutations

No mutations were detected on the loci 93, 97, 101, 145, 146, 158, 159, 343 and 350 among the 602 *P. falciparum* samples. Polymorphism on the locus 356 (I356T) was found in 54.7% (n = 326) of samples (mutants and mixed infection). More precisely, 276 isolates (45.8%) carried the wild type (I356) allele, 294 isolates (48.8%) carried the mutant allele (356T) and 32 isolates (5.4%) were mixed with both wild type and mutant allele (Table 1). Among the 578 samples tested for the 72–76 haplotype (24 were not genotyped successfully), the overall proportion of wild allele K76 was 74.9% (n = 433) versus

20.6% (n = 119) for mutant allele 76T and 4.5% (n = 26) for mixed populations (K76 and 76T) (Table 1). Details of I356T and K76T mutations per country are presented in Table 1. The majority of samples were from West African followed by Central African countries. Because other regions had low samples size, only West African and Central African samples were considered for further analysis. No association between K76T and I356T mutations was found for Central African isolates (n = 209, p = 0.1) while for West African isolates, there was a significant association found (n = 248, p = 0.008).

Drug susceptibility

On the 602 samples collected, 296 isolates (117 from West Africa and 113 from Central Africa) were successfully evaluated in vitro. Values of IC₅₀ estimates ranged from 0.7 nM to 544.0 nM for PPQ (mean = 27.9 nM), 4.1 nM to 474.2 nM for CQ (mean = 59.6 nM), 6.2 nM to 906.3 nM for QN (mean = 179.6 nM), 0.5 nM to 61.5 nM for LMF (mean = 5.2 nM), 2.5 nM to 185.1 nM for DQ (mean = 31.2 nM), 0.6 nM to 133.5 nM for MQ

(mean = 30.5 nM), 0.2 nM to 119.3 nM for PND (mean = 16.4 nM), 0.2 nM to 18.5 nM for DHA (mean = 3.8 nM) and 0.2 nM to 64.0 nM for AS (mean = 2.6 nM) (Fig. 1). Based on the cut-off values for reduced in vitro susceptibility to CQ (100 nM), QN (800 nM), DQ (80 nM), MQ (30 nM), LMF (150 nM), PPQ (135 nM), (PND 60 nM), DHA and AS (10.5 nM) [36, 37], a proportion of samples had an in vitro reduced susceptibility to CQ (16.3%) and MQ (40.2%).

IC₅₀ values were classified in 2 groups based on their genotype for the locus 356. The average parameters estimates of IC₅₀ values for wild type (I356) and mutant allele (356T) for samples from West African and Central African countries are given in Table 2. There was a significant difference between the alleles I356 or 356T and IC₅₀ median values of QN (p = 0.001) and MQ (p = 0.01) in West African group and QN (p = 0.02), CQ (p = 0.01), and MQ (p = 0.04) in Central Africa group (Table 2).

Parasites harbouring the K76T mutation were significantly less susceptible to CQ (p < 0.0002) and DQ (p <




Fig. 1 Dot plot of the IC₅₀ values distribution of *P. falciparum* isolates from West Africa and Central Africa for chloroquine (CQ), quinine (QN), desethylamodiaquine (DQ), lumefantrine (LMF), mefloquine (MQ), piperiaquine (PPQ), dihydroartemisinin (DHA), artesunate (AS) and pyronaridine (PND) according to I356T. Each dot represents the log₁₀(IC₅₀) for each isolate, red dots represent wild type I356 isolates (I), blue dots mutant 356T isolates (T) and yellow dots the log₁₀(median IC₅₀) value for each drug. The y-axis represents the log₁₀(IC₅₀) in nM. * Significant differences were found between wild type (I356) and mutant (356T) in West Africa (QN: p = 0.001, MQ: p = 0.01, PND: p = 0.005) and in Central Africa (QN: p = 0.02, MQ: p = 0.04, CQ: p = 0.01)

Table 2 IC₅₀ average parameters in nM for wild type (I356) and mutant (356T) *P. falciparum* isolates from West Africa and Central Africa for piperazine (PPQ), quinine (QN), mefloquine (MQ), chloroquine (CQ), lumefantrine (LMF), desethylamodiaquine (DQ), pyronaridine (PND), dihydroartemisinin (DHA) and artesunate (AS)

Drugs	West Africa					Central Africa				
	Wild type I356		Mutant 356T		p value	Wild type I356		Mutant 356T		p value
	Median (no)	Min–Max	Median (no)	Min–Max		Median (no)	Min–Max	Median (no)	Min–Max	
PPQ	22.2 (49)	6.8–76.3	19.9 (66)	1.2–544	0.32	24.5 (36)	4.1–79	21.4 (70)	0.67–96.3	0.4
QN	69.1 (49)	11.7–906.3	162.6 (68)	6.2–590.5	<i>0.001</i>	98.2 (36)	17.6–365.2	183.4 (73)	28.9–538.4	<i>0.02</i>
MQ	30.4 (49)	2.9–89.8	22.4 (67)	0.8–100.6	<i>0.01</i>	33.3 (38)	0.7–97.9	21.5 (72)	0.62–133.9	<i>0.04</i>
CQ	37.4 (49)	6.2–283.2	26.5 (68)	5.5–359.5	0.1	42.8 (39)	4.1–474.2	26.9 (73)	5.79–325	<i>0.01</i>
LMF	3.0 (49)	0.5–61.54	4.0 (68)	0.6–18.2	0.6	2.8 (40)	0.6–15.5	3.6 (73)	0.55–22.4	0.5
DQ	19.2 (49)	3.4–169.2	27.1 (68)	2.5–185.1	0.07	22.8 (40)	5.1–152.8	20.8 (73)	4.7–152.9	0.4
PND	8.8 (48)	1.2–50.1	14.5 (66)	0.7–119.3	<i>0.005</i>	11.1 (38)	3.9–41	12.3 (67)	0.2–47.9	0.8
DHA	2.9 (49)	0.4–8.3	3.1 (68)	0.2–12.8	0.9	3.5 (40)	0.7–7.7	2.1 (73)	0.47–11.1	0.08
AS	1.8 (49)	0.4–15.48	1.8 (67)	0.2–9.8	0.6	2.5 (39)	0.6–5.7	1.7 (71)	0.29–30.2	0.05

West Africa: Benin, Burkina Faso, the Gambia, Ghana, Guinea, Ivory Coast, Niger, Mali, Nigeria and Togo

Central Africa: Cameroon, Central African Republic, Chad, Gabon and Republic of Congo

Italic p values refers to significant difference ($p < 0.05$)

Table 3 IC₅₀ average parameters in nM for wild type (K76) and mutant (76T) *P. falciparum* isolates from West Africa and Central Africa for piperazine (PPQ), quinine (QN), mefloquine (MQ), chloroquine (CQ), lumefantrine (LMF), desethylamodiaquine (DQ), pyronaridine (PND), dihydroartemisinin (DHA) and artesunate (AS)

Drugs	West Africa					Central Africa				
	Wild type K76 (n = 76)		Mutant 76T (n = 27)		p value	Wild type K76 (n = 82)		Mutant 76T (n = 14)		p value
	Median	Min–Max	Median	Min–Max		Median	Min–Max	Median	Min–Max	
CQ	23.2	5.5–229.6	152.6	7.9–381	<i>4.295E–10</i>	28.7	5.1–474.4	113.1	14.2–325	<i>0.0002</i>
DQ	19.3	2.5–185.1	46.2	6.5–169.2	<i>0.0002</i>	20.1	4.7–85.8	32.9	16.3–152.9	<i>0.002</i>
QN	138.6	6.2–906.3	163.8	36.7–586	0.2	143.9	28.9–538.4	180.1	17.6–503	0.52
LMF	3.9	0.5–31.6	3.5	0.5–61.5	0.3	3.1	0.5–27.3	4.9	0.6–14.2	0.758
MQ	25.2	0.8–89.8	26.2	2.9–76.7	0.8	23.7	1.04–86.6	40.9	0.7–92.3	0.11
DHA	2.9	0.2–12.8	2.8	0.5–8.2	0.9	2.9	0.5–18.5	2.9	0.7–6.5	0.78
PND	11.8	1.1–119.3	13.3	1.9–50.2	0.7	11.3	0.2–46.6	12.3	2.7–40.8	0.99
AS	1.8	0.3–64	2.1	0.4–7.3	0.8	1.9	0.3–30.2	3.0	0.6–5.9	0.36
PPQ	20.2	1.2–78.9	28.6	7.4–544	0.08	20.6	0.7–84.6	20.9	3.4–67.1	0.82

West Africa: Benin, Burkina Faso, Gambia, Ghana, Guinea, Ivory Coast, Niger, Mali, Nigeria and Togo

Central Africa: Cameroon, Central African Republic, Chad, Gabon and Republic of Congo

Italic p values refers to significant difference ($p < 0.05$)

0.002) in Africa (Table 3). PPQ susceptibility was not significantly associated with the K76T mutation.

Discussion

Understanding the genetic profile of drug resistance genes in *P. falciparum* malaria in endemic countries is essential. Knowing the predominant genotype circulating in a country or a region provide to policy makers a valuable information for the treatment regiments to

be adopted depending on the predominant resistance genetic marker.

Mutations within the *pfcr* haplotype 72–76 are known to confer resistance to chloroquine and other quinine drugs, like amodiaquine and lumefantrine [1, 3, 38, 39]. As already documented many dozens of times, the present results show that the K76T mutation is associated with in vitro resistance to chloroquine and desethylamodiaquine and is an excellent molecular marker of

resistance to chloroquine and amodiaquine for resistance monitoring in Africa. In contrast, the K76T mutation did not appear to be associated with in vitro reduced susceptibility to piperaquine (Table 3), confirming previous results [21, 38].

Previous studies found several new mutations in *pfprt* associated with piperaquine reduced susceptibility, like the mutations T93S, H97Y, C101E, F145I, M343L and G353V in Cambodian parasites [22, 23, 25–29] and C350R in isolates from French Guiana [24] and Suriname [30]. However in studies on African *P. falciparum* samples, there was no report of identification of these mutations [39, 40]. None of these mutations was identified in the present 602 African isolates. These data suggest a very low prevalence of these mutations in African parasites, certainly due to the very low prevalence of *P. falciparum* parasites resistant to piperaquine in Africa. The present results suggest that susceptible parasites to piperaquine do not carry these mutations before selection pressure. The three isolates with piperaquine IC₅₀ above the threshold of reduced susceptibility (135 nM) carried none of these mutations. Moreover, the absence of mutation on codon 93, 97, 101, 145, 146, 158, 159, 343 and 350 suggest that these mutations are not associated with in vitro resistance to amino-quinoline (chloroquine, amodiaquine) or amino-alcohol compounds (mefloquine) in Africa.

The mutation I356T found in 54.7% of isolates in the present work was already identified. The I356T mutation was previously reported at a rate of 24% in *P. falciparum* parasites from Malaysia [41]. In a local and global epidemiological study on global spread of mutant PfCRT, the I356T mutation was found in 12.6% of the *P. falciparum* isolates tested in Africa in 2011–2012 and mainly in the Gambia (78.7%) and the Democratic Republic of Congo (36.5%), and in 70.1% of isolates from Asia and from Thailand (99.2%) and Cambodia (67.7%) [42]. The I356T mutation was detected in 2.4% of isolates, as mixed infections (I356 and 356T alleles) collected before artemether-lumefantrine treatment in Uganda in 2014 [43]. This mutation was not found in *P. falciparum* positive isolates after artemether-lumefantrine treatment. A different amino acid substitution on the locus 356 (I356L) was also found in isolates from Latin America [1, 30], but this mutation was absent the present 602 African isolates. However, this mutation was not observed in isolates from Suriname [30].

The present study shows that the mutation I356T seems to be involved in quinine and mefloquine susceptibilities in African *P. falciparum* parasites. The mutation I356T is significantly associated with reduced susceptibility to quinine and increased susceptibility to mefloquine (Table 2). This mutation is also significantly associated

with increased susceptibility to chloroquine but only in isolates from Central Africa. Additionally, this mutation is significantly associated with decreased susceptibility to pyronaridine but only in West African parasites. This mutation is not associated with piperaquine susceptibility, arguing against a role for residue 356 in modeling *P. falciparum* susceptibility to piperaquine. These data confirm the results of Dhingra et al. [42], that showed no difference in the survival of *P. falciparum* parasites with the FCB (I356) and Dd2 (356T) alleles in the presence of piperaquine. Additionally, the I356T mutation was not associated with ex vivo susceptibility to lumefantrine in the present 602 isolates according to previous data showing that this mutation was not selected in recrudescing *P. falciparum* parasites after artemether-lumefantrine [43].

Allelic frequencies of K76T and I356T in Central Africa show that there is no association with the two alleles. But on West African isolates, a significant association ($p = 0.008$) was found.

None of the mutations in PfCRT associated with in vivo piperaquine resistance in Asia or in vitro resistance in South America (T93S, H97Y, C101E, F145I, M343L, C350R and G353V) were found in the three isolates with ex vivo reduced susceptibility to piperaquine. All these isolates carried the I356T mutation and two the K76T mutation. Only one copy of *pfpm2* was detected in the three isolates in a previous work [19]. But one of the weaknesses of the study is the low number of samples with reduced susceptibility to piperaquine. Further investigations are required to understand piperaquine resistance in Africa where dihydroartemisinin-piperaquine treatment remains highly effective [44].

Conclusion

None of the mutations in *pfprt* found to be associated with piperaquine reduced susceptibility in Asia or South America (T93S, H97Y, C101E, F145I, M343L, C350R and G353V) were found in the 602 African isolates including the three isolates with reduced susceptibility to piperaquine. The K76T mutation, involved in resistance to chloroquine and amodiaquine, and the 356T mutation were not associated with in vitro reduced susceptibility to piperaquine. Differences in mefloquine susceptibility between I356 and 356T isolates were, while statistically different, minimal. Further analyses are needed with a more important sample size from the same geographic area to confirm the role of the I356T mutation on quinine susceptibility.

Abbreviations

AS: Artesunate; CQ: Chloroquine; DHA: Dihydroartemisinin; DNA: Deoxyribonucleic acid; dNTP: Deoxynucleotide triphosphate; DQ: Monodesethylamodiaquine; ELISA: Enzyme linked immunosorbent assay; HRP2: Histidine-rich

protein 2; IC₅₀: 50% inhibitory concentration; LMF: Lumefantrine; MQ: Mefloquine; PCR: Polymerase chain reaction; PfCRT: *Plasmodium falciparum* chloroquine resistance transporter; PfK13: *Plasmodium falciparum* Kelch 13; *Pfpm2*: *Plasmodium falciparum* plasmeprin 2 gene; PND: Pyronaridine; PPQ: Piperazine; QN: Quinine; WHO: World Health Organization.

Acknowledgements

The authors thank the patients and the staff of the hospitals of the French National Reference Center for Imported Malaria network.

The members of the French National Reference Centre for Imported Malaria Study Group are as follow: V Augis (Groupe Hospitalier Pellegrin, Bordeaux), P Bastien (Centre Hospitalier Universitaire de Montpellier, Montpellier), F Benoit-Vical (Centre Hospitalier Universitaire de Rangueil, Toulouse), A Berry (Centre Hospitalier Universitaire de Rangueil, Toulouse), P Brouqui (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), P Chauvin (Centre Hospitalier Universitaire de Rangueil, Toulouse), M Cividin (Centre Hospitalier du Pays d'Aix, Aix en Provence), F Courtier (Centre Hospitalier de Valence), P Delaunay (Centre Hospitalier Universitaire de l'Archet, Nice), L Delhaes (Groupe Hospitalier Pellegrin, Bordeaux), M Drancourt (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), N Dubosc (Centre Hospitalier Robert Boulin, Libourne), T Gaillard (Hôpital d'Instruction des Armées Desgenettes, Lyon), A Genin (Centre Hospitalier du Pays d'Aix, Aix en Provence), E Garnotel (Hôpital d'Instruction des Armées Laveran, Marseille), E Javelle (Hôpital d'Instruction des Armées Laveran, Marseille), C L'Ollivier (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), JC Lagier (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), E Ledault (Hôpital d'Instruction des Armées Laveran, Marseille), M Leveque (Centre Hospitalier Universitaire de Montpellier, Montpellier), D Malvy (Groupe Hospitalier Pellegrin, Bordeaux), P Marty (Centre Hospitalier Universitaire de l'Archet, Nice), G Ménard (Hôpital d'Instruction des Armées Saint-Anne, Toulon), E Menu (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), P Millet (Groupe Hospitalier Pellegrin, Bordeaux), P Minodier (Hôpital Nord, Marseille), P Parola (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), S Picot (Hôpital de la Croix Rousse, Lyon), C Pomares-Estran (Centre Hospitalier Universitaire de l'Archet, Nice), S Ranque (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), M-C Receveur (Groupe Hospitalier Pellegrin, Bordeaux), A Robin (Centre Hospitalier du Pays d'Aix, Aix en Provence), E Sappa (Centre Hospitalier du Pays d'Aix, Aix en Provence), H Savini (Hôpital d'Instruction des Armées Laveran, Marseille), J Sevestre (Institut Hospitalo-Universitaire Méditerranée Infection, Marseille), F Simon (Hôpital d'Instruction des Armées Laveran, Marseille), Y Sterkers (Centre Hospitalier Universitaire de Montpellier, Montpellier), C Surcouf (Hôpital d'Instruction des Armées Laveran, Marseille), E Varlet (Centre Hospitalier Universitaire de Montpellier, Montpellier), A Wolff (Hôpital d'Instruction des Armées Laveran, Marseille).

Authors' contributions

FTF, MG, NB and RA carried out the molecular studies. JM and IF carried out the ex vivo evaluation of anti-malarial drug susceptibility. BP, SW and MM conceived and coordinated the study. FTF, HB, MM and BP analysed the data and drafted the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by the French Institute for Public Health Surveillance (Santé Publique France, grant CNR paludisme) and the Délégation Générale pour l'Armement (Grant No PDH-2-NRBC-4-B-4104). Francis Foguim was supported by the Foundation Méditerranée Infection.

Availability of data and materials

The datasets analysed in this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Informed consent was not required for this study because this work was performed under the statutory auspices of the French national reference centre for imported malaria, and isolates were anonymised by re-coding. Additionally, bio-banking of human clinical samples used for malaria diagnostics and secondary uses for scientific purposes are possible as long as the corresponding patients are informed and have not indicated any objections. This requirement was fulfilled here by giving verbal information to the patients, and no immediate or delayed patient opposition was reported to the hospital clinicians.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Unité Parasitologie et entomologie, Département Microbiologie et maladies infectieuses, Institut de Recherche Biomédicale des Armées, IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005 Marseille, France. ² Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France. ³ IHU Méditerranée Infection, Marseille, France. ⁴ Centre National de Référence du Paludisme, Marseille, France. ⁵ Laboratory of Pathogen Host Interactions, UMR 5235, CNRS-Université de Montpellier, Montpellier, France.

Received: 7 November 2019 Accepted: 30 May 2020

Published online: 05 June 2020

References

- Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol Cell*. 2000;6:861–71.
- Nqoro X, Tobeka N, Aderibigbe BA. Quinoline-based hybrid compounds with antimalarial activity. *Molecules*. 2017;22:2268.
- Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A molecular marker for chloroquine-resistant *falciparum* malaria. *N Engl J Med*. 2001;344:257–63.
- Gabryszewski SJ, Dhingra SK, Combrinck JM, Lewis IA, Callaghan PS, Hassett MR, et al. Evolution of fitness cost-neutral mutant PfCRT conferring *P. falciparum* 4-aminoquinoline drug resistance is accompanied by altered parasite metabolism and digestive vacuole physiology. *PLoS Pathog*. 2016;12:e1005976.
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2014;371:411–23.
- Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiology observational study. *Lancet Infect Dis*. 2017;17:491–7.
- Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperazine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet Infect Dis*. 2016;16:357–65.
- Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of *Plasmodium falciparum* malaria multidrug resistance to artemisinin and piperazine in Western Cambodia: dihydroartemisinin-piperazine open-label multicenter clinical assessment. *Antimicrob Agents Chemother*. 2015;59:4719–26.
- Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperazine failure associated with a triple mutant including *kelch13* C580Y in Cambodia: an observational cohort study. *Lancet Infect Dis*. 2015;15:683–91.
- Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, Ménard D, et al. Treatment failure of dihydroartemisinin/piperazine for *Plasmodium falciparum* malaria, Vietnam. *Emerg Infect Dis*. 2017;23:715–7.
- Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of *Plasmodium falciparum* to dihydroartemisinin-piperazine in the south of Vietnam. *Malar J*. 2017;16:27.
- Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperazine-resistant *Plasmodium falciparum* malaria: a phenotype-genotype association study. *Lancet Infect Dis*. 2017;17:174–83.
- Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin-piperazine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype-phenotype association study. *Lancet Infect Dis*. 2017;17:164–73.

14. Foguim Tsombeng F, Gendrot M, Robert MG, Madamet M, Pradines B. Are k13 and plasmepsin II genes, involved in *Plasmodium falciparum* artemisinin derivatives and piperazine resistance in Southeast Asia, reliable to monitor resistance surveillance in Africa? *Malar J*. 2019;18:285.
15. Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy and molecular markers for artemisinin and piperazine resistance in Mailand Tanzania. *Malar J*. 2018;17:369.
16. Russo G, L'Episcopia M, Menegon M, Souza SS, Dongho BGD, Vullo V, et al. Dihydroartemisinin-piperazine treatment failure in uncomplicated *Plasmodium falciparum* malaria case imported from Ethiopia. *Infection*. 2018;46:867–70.
17. Malvy D, Torrentino-Madamet M, L'Ollivier C, Receveur MC, Jeddi F, Delhaes L, et al. *Plasmodium falciparum* recrudescence two years after treatment of an uncomplicated infection without return to an area where malaria is endemic. *Antimicrob Agents Chemother*. 2018;62:e01892–17.
18. Rasmussen SA, Ceja FG, Conrad MD, Tumwebase PK, Byaruhanga O, Katairo T, et al. Changing antimalarial drug sensitivities in Uganda. *Antimicrob Agents Chemother*. 2017;61:e01516–7.
19. Robert MG, Foguim Tsombeng F, Gendrot M, Mosnier J, Amalvict R, Benoit N, et al. Absence of a high level of duplication of the Plasmepsin II gene in Africa. *Antimicrob Agents Chemother*. 2018;62:e00374–18.
20. Robert MG, Foguim Tsombeng F, Gendrot M, Diawara S, Madamet M, Kounta MB, et al. Baseline ex vivo and molecular responses of *Plasmodium falciparum* isolates to piperazine before implementation of dihydroartemisinin-piperazine in Senegal. *Antimicrob Agents Chemother*. 2019;63:e02445–18.
21. Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, et al. In vitro piperazine susceptibility is not associated with the *Plasmodium falciparum* chloroquine resistance transporter gene. *Malar J*. 2013;12:431.
22. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. Piperazine resistance is associated with a copy number variation on chromosome 5 in drug-preserved *Plasmodium falciparum* parasites. *Antimicrob Agents Chemother*. 2011;55:3908–16.
23. Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, et al. A variant PfCRT isoform can contribute to *Plasmodium falciparum* resistance to the first-line partner drug piperazine. *MBio*. 2017;8:e00303–17.
24. Pelleau S, Moss EL, Dhingra SK, Volney B, Casteras J, Gabryszewski SJ, et al. Adaptive evolution of malaria parasites in French Guiana: reversal of chloroquine resistance by acquisition of a mutation in *pfcr1*. *Proc Natl Acad Sci USA*. 2015;112:11672–7.
25. Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the *Plasmodium falciparum* chloroquine resistance transporter with decreased piperazine sensitivity. *J Infect Dis*. 2017;216:468–76.
26. Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kümpornsin K, et al. Emerging Southeast Asian PfCRT mutations confer *Plasmodium falciparum* resistance to the first-line antimalarial piperazine. *Nat Commun*. 2018;9:3314.
27. Dhingra SK, Small-Saunders JL, Ménard D, Fidock DA. *Plasmodium falciparum* resistance to piperazine driven by PfCRT. *Lancet Infect Dis*. 2019;19:1168–9.
28. Van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperazine treatment failure in *Plasmodium falciparum* malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. *Lancet Infect Dis*. 2019;19:952–61.
29. Hamilton WL, Amato R, van der Pluijm RW, Jacobs CG, Quang HH, Thuy-Nhien NT, et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. *Lancet Infect Dis*. 2019;19:943–51.
30. Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vreden S, et al. Molecular profile of malaria drug resistance markers of *Plasmodium falciparum* in Suriname. *Antimicrob Agents Chemother*. 2017;61:e02655–16.
31. Miotto O, Amato R, Ashley EA, Maclinnis B, Almagro-García J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet*. 2015;47:226–34.
32. Gendrot M, Foguim FT, Robert MG, Amalvict R, Mosnier J, Benoit N, et al. The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African *Plasmodium falciparum* isolates. *Malar J*. 2018;17:108.
33. Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, et al. Genetic diversity and structure of African *Plasmodium falciparum* populations in urban and rural areas. *Am J Trop Med Hyg*. 2006;74:953–9.
34. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, et al. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of *Plasmodium falciparum* isolates. *Am J Trop Med Hyg*. 2006;75:146–51.
35. Anderson TJC, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite *Plasmodium falciparum*. *Mol Biol Evol*. 2000;17:1467–82.
36. Pascual A, Madamet M, Briolant S, Gaillard T, Amalvict R, Benoit N, et al. Multinomial in vitro distribution of *Plasmodium falciparum* susceptibility to piperazine and pyronaridine. *Malar J*. 2015;14:49.
37. Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. *Malar J*. 2011;10:268.
38. Mwai L, Kiara SM, Abdurahman A, Pole L, Rippert A, Diriye A, et al. In vitro activities of piperazine, lumefantrine, and dihydroartemisinin in Kenyan *Plasmodium falciparum* isolates and polymorphisms in *pfcr1* and *pfmdr1*. *Antimicrob Agents Chemother*. 2009;53:5069–73.
39. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant *Plasmodium falciparum* malaria in vivo is associated with selection of *pfcr1* 76T and *pfmdr1* 86Y. *Infect Genet Evol*. 2006;6:309–14.
40. Basco LK. Molecular epidemiology of malaria in Cameroon. XIII. Analysis of *pfcr1* mutations and in vitro chloroquine resistance. *Am J Trop Med Hyg*. 2002;67:388–91.
41. Atroosh WM, Al-Mekhlafi HM, Mahdy MAK, Surin J. The detection of *pfcr1* and *pfmdr1* point mutations as molecular markers of chloroquine drug resistance, Pahang, Malaysia. *Malar J*. 2012;11:251.
42. Dhingra SK, Gabryszewski SJ, Small-Saunders JL, Yeo T, Henrich PP, Mok S, et al. Global spread of mutant PfCRT and its pleiotropic impact on *Plasmodium falciparum* multidrug resistance and fitness. *MBio*. 2019;10:e02731–18.
43. Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, et al. Absence of in vivo selection for k13 mutations after artemether-lumefantrine treatment in Uganda. *Malar J*. 2017;16:23.
44. West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperazine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. *Lancet*. 2018;391:1378–90.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.